Ethyl icosapentate

Ethyl icosapentate is a lipid of Fatty Acyls (FA) class.

Cross Reference

There are no associated biomedical information in the current reference collection.

Current reference collection contains 382 references associated with Ethyl icosapentate in LipidPedia. Due to lack of full text of references or no associated biomedical terms are recognized in our current text-mining method, we cannot extract any biomedical terms related to diseases, pathways, locations, functions, genes, lipids, and animal models from the associated reference collection.

Users can download the reference list at the bottom of this page and read the reference manually to find out biomedical information.


Here are additional resources we collected from PubChem and MeSH for Ethyl icosapentate

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with Ethyl icosapentate

MeSH term MeSH ID Detail
Kidney Failure, Chronic D007676 51 associated lipids
Proteinuria D011507 30 associated lipids
Peritoneal Neoplasms D010534 16 associated lipids
Thymus Neoplasms D013953 15 associated lipids
Lupus Nephritis D008181 8 associated lipids
Total 5

NCBI Entrez Crosslinks

All references with Ethyl icosapentate

Download all related citations
Per page 10 20 50 100 | Total 118
Authors Title Published Journal PubMed Link
Bhatt DL et al. Rationale and design of REDUCE-IT: Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention Trial. 2017 Clin Cardiol pmid:28294373
Brinton EA and Mason RP Prescription omega-3 fatty acid products containing highly purified eicosapentaenoic acid (EPA). 2017 Lipids Health Dis pmid:28137294
Mosca L et al. Usefulness of Icosapent Ethyl (Eicosapentaenoic Acid Ethyl Ester) in Women to Lower Triglyceride Levels (Results from the MARINE and ANCHOR Trials). 2017 Am. J. Cardiol. pmid:27939227
Ballantyne CM et al. Icosapent ethyl (eicosapentaenoic acid ethyl ester): Effects on plasma apolipoprotein C-III levels in patients from the MARINE and ANCHOR studies. 2016 May-Jun J Clin Lipidol pmid:27206952
Gose T et al. Prostaglandin transporter (OATP2A1/SLCO2A1) contributes to local disposition of eicosapentaenoic acid-derived PGE3. 2016 Prostaglandins Other Lipid Mediat. pmid:26692285
Bays HE et al. Icosapent ethyl: Eicosapentaenoic acid concentration and triglyceride-lowering effects across clinical studies. 2016 Prostaglandins Other Lipid Mediat. pmid:27418543
Fialkow J Omega-3 Fatty Acid Formulations in Cardiovascular Disease: Dietary Supplements are Not Substitutes for Prescription Products. 2016 Am J Cardiovasc Drugs pmid:27138439
Ballantyne CM et al. Icosapent ethyl (eicosapentaenoic acid ethyl ester): Effects on remnant-like particle cholesterol from the MARINE and ANCHOR studies. 2016 Atherosclerosis pmid:27596132
Braeckman RA et al. Effect of concomitant icosapent ethyl (eicosapentaenoic acid ethyl ester) on the pharmacokinetics of atorvastatin. 2015 Clin Drug Investig pmid:25471740
Yamanushi TT et al. Oral administration of eicosapentaenoic acid or docosahexaenoic acid modifies cardiac function and ameliorates congestive heart failure in male rats. 2014 J. Nutr. pmid:24523492